熱門資訊> 正文

ImmunityBio 2026年第四季度盈利预览

2026-03-03 06:38

ImmunityBio Inc(IBRX) 0
Stride(LRN) 0

ImmunityBio (IBRX) is scheduled to announce Q4 earnings results on Tuesday, March 3rd, after market close.
The consensus EPS Estimate is -$0.08 and the consensus Revenue Estimate is $44.77M (+521.8% Y/Y).
Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

More on ImmunityBio

ImmunityBio: Disconnect Between Clinical Progress And Stock Performance
ImmunityBio: The Story Surrounding Anktiva So Far
ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade)
Top 10 Healthcare Stocks of February
ImmunityBio forms Irish unit, distribution deal to improve Anktiva access in Europe

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。